39P - Evaluation of soluble E-Cadherin as a predictive marker for response to preoperative systemic chemotherapy in early breast cancer
|Date||08 May 2014|
|Session||Welcome reception and Poster Walk|
|Topics|| Breast Cancer, Early Stage
|Citation||Annals of Oncology (2014) 25 (suppl_1): i8-i16. 10.1093/annonc/mdu066|
C. Suppan1, G. Steger2, M. Balic1, N. Dandachi1, A. Lang3, B. Mlineritsch4, C. Fesl5, H. Samonigg1, M. Gnant6, T. Bauernhofer1
Recent studies demonstrated that elevated levels of soluble E-cadherin (sE-cadherin), a product of proteolytic cleavage of cell-surface E-cadherin, are associated with higher risk for metastatic disease and poor prognosis in various tumor types. In a retrospective analysis, we have recently shown a significant association between sE-cadherin levels and histopathological regression scores. ABCSG-24, a randomised phase III trial comparing pathological complete response (pCR) rates of early breast cancer following preoperative systemic chemotherapy (PST) with epirubicin-docetaxel (ED) +/- capecitabine (EDC) with the addition of trastuzumab in Her2-positive tumors, was the perfect opportunity to prospectively evaluate, if sE-cadherin is a predictive marker for response to PST in breast cancer patients.
Materials and methods:
In this prospective analysis, sera of 196 patients undergoing PST for six cycles every three weeks were collected before initiation of each cycle. Soluble E-cadherin measurement was done by using a commercially available quantitative sandwich enzyme immunoassay technique. Histopathological response in surgically removed specimens was evaluated using a modified Sinn regression score. In univariate and multivariate analyses, sE-cadherin was correlated with pCR to PST and clinico-pathological parameters.
The median level of sE-cadherin in the group of patients with pCR was 3864.08 ng/ml (range: 2265.73–6613.84), whereas the median level without pCR was 3738.76 ng/ml (range: 1752.04–10838.16). This difference was not statistically significant (p = 0.31). Furthermore there was no significant difference between the sE-cadherin levels in the two therapy arms (ED vs. EDC). Regarding to clinico-pathological parameters pretreatment sE-cadherin showed a significant correlation with menopausal status (p = 0.036) and tumor grade (p = 0.0093). Histopathological response was significantly associated with hormone receptor status (p < 0.0001) and Her2-neu-status (p = 0.032).
Our findings do not support a predictive or prognostic value of sE-Cadherin in breast cancer patients undergoing PST.
All authors have declared no conflicts of interest.